Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose

Cancer Research

Volumn 67, Issue 14, 2007, Pages 6995-7002

  Brown, Karen ^a,b   Tompkins, Elaine M ^a   Boocock, David J ^a   Martin, Elizabeth A ^d   Farmer, Peter B ^a   Turteltaub, Kenneth W ^e   Ubick, Esther ^e   Hemingway, David ^c   Horner Glister, Emma ^a   White, Ian N H ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; CARBON 14; CARCINOGEN; CYTOCHROME P450 3A4; DNA; DRUG METABOLITE; HYDROXYTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON; COLON CARCINOGENESIS; COLON RESECTION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG LABELING; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 34547105315     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0913     Document Type: Article

References (49)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: a report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998;90:1371-88.
2. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
3. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
4. Brown K. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 2000;1:253-67.
5. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-51.
6. Newcomb PA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 1999;53:271-7.
7. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013-7.
8. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47.
9. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
10. Wilking N, Isaksson E, von Schoultz E. Tamoxifen and secondary tumours - an update. Drug Saf 1997;16:104-17.
11. Greaves P; Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53:3919-24.
12. Phillips DH, Carmichael PL, Hewer A, et al. Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996;17:89-94.
13. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White INH. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002;23:1897-901.
14. White INH. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab 2003;4:223-39.
15. Osborne MR, Hewer A, Hardcastle IR, Carmichael PL, Phillips DH. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 1996;56:66-71.
16. Dasaradhi L, Shibutani S. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem Res Toxicol 1997;10:189-96.
17. McLuckie KIE, Crookston RJR, Gaskell M, et al. Mutation spectra induced by α-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (Xeroderma Pigmentosum Complementation Group A) cells. Biochemistry 2005;44:8198-205.
18. 2-deoxyguanosinyl) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 1999;59:2091-5.
19. Brown K, Heydon RT, Jukes R, White INH, Martin EA. Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis 1999;20:2011-6.
20. Gamboa da Costa G, Hamilton LP, Beland FA, Marques MM. Characterization of the major DNA adduct formed by α-hydroxy-N-desmethyltamoxifen in vitro and in vivo. Chem Res Toxicol 2000;13:200-7.
21. Umemoto A, Monden Y, Lin CX, et al. Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen. Chem Res Toxicol 2004;17:1577-83.
22. Shibutani S, Ravindernath A, Suzuki N, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000;21:1461-7.
23. Shibutani S, Suzuki N, Terashima I, et al. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. ChemRes Toxicol 1999;12:646-53.
24. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J Natl Cancer Inst 2004;96:1099-104.
25. Carmichael PL, Ugwumadu AHN, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996;56:1475-9.
26. Brown K, Tompkins EM, White INH. Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spectrom Rev 2006;25:127-45.
27. Martin EA, Brown K, Gaskell M, et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003;63:8461-5.
28. Foster AB, Jarman M, Leung O, McCague R, Leclercq G, Devleeschouwer N. Hydroxy derivatives of tamoxifen. J Med Chem 1985;28:1491-7.
29. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. Report to the General Assembly. New York: UNSCEAR; 2000.
30. Brown K, Dingley KH, Turteltaub KW. Accelerator mass spectrometry for biomedical research. Methods Enzymol 2005;402:423-43.
31. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormonetherapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106:574-82.
32. Al Azzawi F, Wahab M. Estrogen and colon cancer: current issues. Climacteric 2002;5:3-14.
33. Anonymous. IARC Monographs on the evaluation of carcinogenic risks to humans. 1996;66:253-365.
34. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979;27:145-7.
35. Poon GK, Walter B, Lønning PE, Horton MN, McCague R. Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate and patients on long-term therapy for breast cancer. Drug Metab Dispos 1995;23:377-82.
36. Davis W, Venitt S, Phillips DH. The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 1998;19:861-6.
37. Glatt H, Davis W, Meinl W, Hermersdörfer H, Venitt S, Phillips DH. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 1998;19:1709-13.
38. Shibutani S, Shaw PM, Suzuki N, et al. Sulfation of α- hydroxytamoxifen catalysed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 1998;19:2007-11.
39. Chen GP, Zhang DQ, Jing N, et al. Human gastrointestinal sulfotransferases: identification and distribution. Tox Appl Pharmacol 2003;187:186-97.
40. Phillips DH, Hewer A, Osborne MR, Cole KJ, Churchill C, Arlt VM. Organ specificity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 2005;20:297-303.
41. Schild LJ, Divi RL, Beland FA, et al. Formation of tamoxifen-DNA adducts in multiple organs of adult female Cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 2003;63:5999-6003.
42. Shibutani S, Suzuki N, Laxmi YRS, et al. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 2003;63:4402-6.
43. Beland FA, Marques MM, da Costa GG, Phillips DH. Tamoxifen-DNA adduct formation in human endometrium. Chem Res Toxicol 2005;18:1507-9.
44. Osborne MR, Hardcastle IR, Phillips DH. Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis 1997;18:539-43.
45. Malfatti MA, Dingley KH, Nowell-Kadlubar S, et al. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 2006;66:10541-7.
46. Boocock DJ, Maggs JL, Brown K, White INH, Park BK. Major interspecies differences in the rates of O-sulphonation and O-glucuronylation of α-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 2000;21:1851-8.
47. Dingley KH, Curtis KD, Nowell S, Felton JS, Lang NP, Turteltaub KW. DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine. Cancer Epidemiol Biomarkers Prev 1999;8:507-12.
48. Mauthe RJ, Dingley KH, Leveson SH, et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int J Cancer 1999; 80:539-45.
49. Lightfoot TJ, Cupid BC, Nicholson S, Leveson SH, Alexander DJ, Garner RC. The use of accelerator mass spectrometry in cancer risk assessment following dietary exposure to heterocyclic amines and polycyclic aromatic hydrocarbons. Toxicology 2001;168:89-90.